Literature DB >> 9039108

The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension.

H Hayakawa1, L Raij.   

Abstract

The adaptive changes that occur in the left ventricle (LV) and vessels in response to hypertension, namely, muscle hypertrophy/hyperplasia, endothelial dysfunction, and extracellular matrix increase, do not depend solely on blood pressure elevation. These changes are in fact, maladaptive since they are forerunners of cardiac failure, stroke, and renal failure. Nitric oxide, an endogenous vasodilator and inhibitor of vascular smooth muscle cell growth, is synthesized in the endothelium by constitutive nitric oxide synthase (cNOS). We investigated the relationships among LV and aortic cNOS activity (conversion of [14C] L-arginine to [14C] L-citrulline), with LV hypertrophy (LV weight/body weight), and (2) aortic hypertrophy (aortic weight/ length) in spontaneously hypertensive rats (SHR) and Dahl salt-sensitive (DS) rats matched for blood pressure (219 +/- 12 versus 211 +/- 7 mm Hg, P = NS) and age. Compared with their normotensive counterparts, aortic cNOS activity was increased 106% in SHR but reduced by 73% in DS rats. The correlation between blood pressure and aortic cNOS activity was positive (r = .74, P < .01) in SHR and negative (r = -.82, P < .01) in DS rats, LV cNOS activity was increased 73% in SHR compared with normotensive Wistar-Kyoto rats (P < .01). On the other hand, LV cNOS activity was not increased in hypertensive DS rats compared with normotensive DS rats. In SHR, aortic hypertrophy did not increase significantly and LV hypertrophy increased only 15%, whereas in hypertensive DS rats the aorta and LV hypertrophied 36% and 88%, respectively (both P < .01). Moreover, in DS rats there was a negative correlation between cNOS activity and aortic hypertrophy (r = -.70, P < .01). In DS rats, antihypertensive therapy consisting of an angiotensin-converting enzyme inhibitor, perindopril, and a diuretic, indapamide, normalized blood pressure, aortic cNOS activity, and LV hypertrophy and reduced aortic hypertrophy. Our studies imply that upregulation of vascular cNOS activity has a protective cardiovascular homeostatic role in hypertension. Clinically, the variable end-organ disease observed in individuals with similar severity of hypertension may be explained, at least in part, by genetically conditioned differences in vascular cNOS activity in response to hypertension.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9039108     DOI: 10.1161/01.hyp.29.1.235

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  21 in total

1.  The role of myocardial perfusion imaging in vascular endothelial dysfunction.

Authors:  V Dilsizian
Journal:  J Nucl Cardiol       Date:  2000 Mar-Apr       Impact factor: 5.952

Review 2.  Long-term blood pressure control: is there a set-point in the brain?

Authors:  Yasuhiro Nishida; Megumi Tandai-Hiruma; Takehito Kemuriyama; Kohsuke Hagisawa
Journal:  J Physiol Sci       Date:  2012-05       Impact factor: 2.781

3.  The 894T allele of endothelial nitric oxide synthase gene is related to left ventricular mass in African Americans with high-normal blood pressure.

Authors:  Rigobert Lapu-Bula; Alexander Quarshie; Deborah Lyn; Adefisayo Oduwole; Cheryl Pack; Jan Morgan; Sunday Nkemdiche; Priscilla Igho-Pemu; Anekwe Onwuanyi; Rongling Li; Elizabeth Ofili
Journal:  J Natl Med Assoc       Date:  2005-02       Impact factor: 1.798

4.  Influence of hypertension on nitric oxide synthase expression and vascular effects of lipopolysaccharide in rat mesenteric arteries.

Authors:  A M Briones; M J Alonso; J Marín; G Balfagón; M Salaices
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 5.  Vasopeptidase inhibition and endothelial function in hypertension.

Authors:  L V d'Uscio; T F Lüscher
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 6.  Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension.

Authors:  A J Matheson; S M Cheer; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  Pharmacological properties of indapamide. Rationale for use in hypertension.

Authors:  A Bataillard; P Schiavi; J Sassard
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

8.  Synergism of irbesartan and amlodipine on hemodynamic amelioration and organ protection in spontaneously hypertensive rats.

Authors:  Wen Shang; Ping Han; Cheng-bing Yang; Xiao-wen Gu; Wei Zhang; Li-ping Xu; Shou-ting Fu; Ding-feng Su; He-hui Xie
Journal:  Acta Pharmacol Sin       Date:  2011-08-01       Impact factor: 6.150

9.  AHA/ACC-defined stage 1 hypertensive adults do not display cutaneous microvascular endothelial dysfunction.

Authors:  Gabrielle A Dillon; Jody L Greaney; Sean Shank; Urs A Leuenberger; Lacy M Alexander
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-07-31       Impact factor: 4.733

10.  Downregulation of vascular soluble guanylate cyclase induced by high salt intake in spontaneously hypertensive rats.

Authors:  S Kagota; A Tamashiro; Y Yamaguchi; R Sugiura; T Kuno; K Nakamura; M Kunitomo
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.